1. Keenan BP, Jaffee EM . Whole cell vaccines-past progress and future strategies. Semin Oncol 2012; 39: 276–286.
2. Eager R, Nemunaitis J . GM-CSF gene-transduced tumor vaccines. Mol Ther 2005; 12: 18–27.
3. Higano CS, Somer F, Curti B, Petrylak B, Drake D, Schnell C et al. A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC). ASCO Genitourinary Cancers Symposium 2009, LBA150.
4. Small ED, Gerritsen T, Rolland W, Hoskin F, Smith P, Parker D et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer. ASCO Genitourinary Cancers Symposium 2009: 7.
5. Kennedy MK, Glaccum M, Brown SN, Butz EA, Viney JL, Embers M et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 2000; 191: 771–780.